step semaglutide mean weight reduction of 9.6% over 68 weeks - STEP1 trial extensionsemaglutide Wegovy® (semaglutide) injection 2.4 mg or tablets 25 mg Unpacking the STEP Semaglutide Trials: A Deep Dive into Obesity Treatment

STEP5semaglutide The Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program represents a significant advancement in the pharmacological management of obesity. This comprehensive series of studies has meticulously investigated the efficacy and safety of once-weekly injectable semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, as a tool for weight management. The overarching goal of these trials has been to provide robust, evidence-based data on how semaglutide can contribute to substantial and sustained weight reduction in individuals struggling with overweight and obesity.作者：JPH Wilding·2021·被引用次数：5149—Theglobal phase 3 Semaglutide Treatment Effect in People with Obesity (STEP) program aims to evaluate the efficacy and safety of semaglutide ...

The STEP program encompasses several key trials, each designed to address specific aspects of semaglutide's effectiveness and tolerability.STEP6: Research Study Investigating How WellSemaglutideWorks in People Living With Overweight or Obesity (STEP6). ClinicalTrials.gov ID NCT03811574. These trials have consistently demonstrated that semaglutide, particularly at a 2.4 mg dosage, when used as an adjunct to a reduced-calorie diet and increased physical activity, leads to significant improvements in body weight.Search Lilly clinical trialsto find an appropriate trial near you or a loved one, or sign up to receive alerts on Lilly trials. For instance, the STEP 1 trial was pivotal in showing that once-weekly semaglutide was superior to placebo at improving weight loss. This trial established a strong foundation, with participants achieving a mean weight reduction of 9.6% over 68 weeksOnce-weekly semaglutide 2·4 mg in an Asian population ....

Further expanding on these findings, the STEP 4 withdrawal trial focused on the sustainability of semaglutide's effects. This study compared the outcomes of continuing once-weekly treatment with subcutaneous semaglutide, 2.4 mg, versus discontinuing it after an initial period. The results underscored the necessity of continued treatment for maintaining weight loss, highlighting the long-term benefits of this approach.Effect of Continued Weekly Subcutaneous Semaglutide vs ...

The exploration of higher dosages has also been a critical component of the STEP initiativeOnce-weekly semaglutide 7·2 mg in adults with obesity .... The STEP UP Trial and studies involving Semaglutide 7.2 mg have indicated that Semaglutide 7作者：S Wharton·2025·被引用次数：32—Semaglutide 7·2 mg was superior to placebo and 2·4 mgfor bodyweight reduction in adults with obesity, while retaining a favourable risk–benefit ....2 mg was superior to placebo and 2.4 mg for bodyweight reduction in adults with obesity, while retaining a favorable risk-benefit profile. In some instances, Semaglutide 7Find Lilly Clinical Trials.2 mg significantly outperformed semaglutide 2Semaglutide - StatPearls - NCBI Bookshelf.4 mg and placebo with substantial average reductions in weight.

Administration of semaglutide in these trials typically involves injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The dosing regimen often begins with a lower dose, such as 0.25 mg once a week for the first 4 weeks, to allow the body to adapt to the medication. This gradual dose escalation is a common strategy to enhance tolerability and minimize potential side effects.

Beyond general weight loss, the STEP trials have also delved into the effects of semaglutide on specific populations and outcomes.作者：WT Garvey·2022·被引用次数：877—In STEP 5,once-weekly treatment with semaglutide 2.4 mgas an adjunct to behavioral intervention in adults with overweight (with at least one ... STEP 5, for example, investigated once-weekly treatment with semaglutide 2.Two-year effects of semaglutide in adults with overweight ...4 mg as an adjunct to behavioral intervention in adults with overweight (with at least one comorbid condition)Weight Management for Adults with Obesity | Wegovy .... Other research from the program has examined the effect of semaglutide on body composition and proximal muscle function, suggesting broader physiological benefits beyond just scale weight.

The global phase 3 Semaglutide Treatment Effect in People with Obesity (STEP program) has been instrumental in shaping current understanding and clinical practice. Specifically, STEP 7 was a multiregional randomised clinical trial conducted to compare the efficacy and safety of semaglutide 2.4 mg versus placebo, as an adjunct to a lifestyle intervention, further solidifying the drug's role.STEP6: Research Study Investigating How WellSemaglutideWorks in People Living With Overweight or Obesity (STEP6). ClinicalTrials.gov ID NCT03811574. Similarly, STEP 11 was a 44-week trial conducted in an Asian population, demonstrating the drug's efficacy across diverse ethnic groups.

The data generated from the STEP trials has directly informed regulatory approvals. Semaglutide 2.2025年1月17日—Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mgand placebo with a 20.7% average reduction in weight and a comparable safety and tolerability ...4 mg is FDA-approved for weight management and is available in different forms, including Wegovy® (semaglutide) injection 2.4 mg or tablets 25 mg, specifically for adults and adolescents with obesity or overweight with at least one weight-related condition作者：S Wharton·2025·被引用次数：32—Semaglutide 7·2 mg was superior to placebo and 2·4 mgfor bodyweight reduction in adults with obesity, while retaining a favourable risk–benefit .... For type 2 diabetes management, Ozempic® (semaglutide) injection 0FDA's Concerns with Unapproved GLP-1 Drugs Used for ....5 mg, 1 mg, or 2 mg is an injectable prescription medicine used alongside diet and exercise to improve blood sugar control. It is important to note that GLP-1s are medicines licensed to treat specific medical disorders and should only be used if you are overweight or diabetic, and not if you want to lose weight solely for cosmetic reasonsFind Lilly Clinical Trials.

The broader implications of the STEP program extend to ongoing research and the search for clinical trials.Effect of Continued Weekly Subcutaneous Semaglutide vs ... Entities like Novo Nordisk Patient Assistance Program (PAP) offer support for patients utilizing semaglutide medicationsSemaglutide - StatPearls - NCBI Bookshelf. Exploring Lilly clinical trials can also be relevant for individuals seeking participation in or information about pharmaceutical research and development in related areas. As the field of obesity treatment continues to evolve, the contributions of the STEP trials remain a cornerstone of evidence-based care, offering hope and viable solutions for individuals managing their weight.